Vx 001

Drug Profile

Vx 001

Alternative Names: hTERT572Y/hTERT572; Human telomerase reverse transcriptase 572Y; TERT572Y; Vx-001; Vx-001/hTERT

Latest Information Update: 22 Apr 2016

Price : $50

At a glance

  • Originator Vaxon Biotech
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Non-small cell lung cancer

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 07 Sep 2015 No recent reports on development identified - Phase-I/II for Solid tumours in Greece (SC)
  • 07 Sep 2015 Phase-II clinical trials in Non-small cell lung cancer in Czech Republic, France, Germany, Italy, Poland, Romania and Spain (SC)
  • 07 Sep 2015 Vx 001 is still in phase II trials for Non-small cell lung cancer in Greece
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top